Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Increased by Jacobs & Co. CA

Jacobs & Co. CA lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,191 shares of the biopharmaceutical company’s stock after purchasing an additional 64 shares during the quarter. Jacobs & Co. CA’s holdings in Regeneron Pharmaceuticals were worth $6,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in REGN. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth $37,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $39,000. Finally, Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at $39,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Leerink Partners reissued a “market perform” rating and set a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday. Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,037.33.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $38.89 on Friday, reaching $694.70. The stock had a trading volume of 700,147 shares, compared to its average volume of 682,965. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a fifty day moving average of $754.37 and a two-hundred day moving average of $965.13. Regeneron Pharmaceuticals, Inc. has a 1-year low of $691.00 and a 1-year high of $1,211.20. The company has a market cap of $76.34 billion, a P/E ratio of 17.19, a price-to-earnings-growth ratio of 2.19 and a beta of 0.10.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.